Chlamydia W5
Description
The E.coli derived recombinant 6x His fusion at C-terminus protein contains Chlamydia Trachomatis MOMP protein epitopes, 252-354 amino acids, and a 6xHis Tag fused at C-terminus.
Product Specs
Product Science Overview
Researchers have been working on identifying novel antigens for a potential vaccine against Chlamydia trachomatis. These antigens are crucial for eliciting an immune response that can protect against infection. The identification process involves various techniques such as CD4+ and CD8+ T-cell expression cloning, serological expression cloning, and in silico analysis of the Chlamydia trachomatis genome . These methods help in pinpointing antigens that can trigger a protective immune response.
The development of a Chlamydia vaccine has faced several challenges. One of the main hurdles is the need for a multivalent subunit cocktail of antigens to provide broad coverage for a heterogeneous major histocompatibility complex population . This means that the vaccine needs to be effective across different genetic backgrounds to ensure widespread protection.
Studies have shown that certain proteins, such as the major outer membrane protein (MOMP) and polymorphic membrane proteins (Pmps) E, F, G, and H, can elicit protective immunity . These proteins have been tested in murine models and have shown promising results in terms of inducing an immune response that can protect against Chlamydia trachomatis infection . Human studies have also indicated that interferon-gamma (IFN-γ) responses to these proteins are associated with a decrease in incident chlamydia and reinfection .
Despite the availability of effective treatments, Chlamydia trachomatis infection rates have not decreased significantly . This highlights the urgent need for a vaccine to help reduce infection rates and preserve reproductive health. A vaccine would be a crucial tool in controlling the spread of Chlamydia and preventing the long-term health complications associated with the infection .
In conclusion, the development of a Chlamydia trachomatis vaccine, including the W5 recombinant, is a critical step towards controlling this widespread infection. The identification of novel antigens and understanding the immune responses they elicit are key components in the development of an effective vaccine.
